Product image of Intesticortmono (Budesonide) supplied by GNH India

Intesticortmono

Active Ingredient:
Budesonide
Origin:
EU

Intesticortmono (Budesonide)

Budesonide, the active ingredient in Intesticortmono, is a corticosteroid presented as an oral formulation for systemic use. It is employed to reduce inflammation in specific gastrointestinal and esophageal disorders, particularly in adult patients with Crohn's disease, ulcerative colitis, or eosinophilic esophagitis.

GNH India supplies Intesticortmono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Dr. Falk Pharma G.M.B.H.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Intesticortmono (budesonide) is a glucocorticoid that targets inflammatory pathways in the gastrointestinal tract and esophagus.

  • Crohn's disease: helps achieve remission of intestinal inflammation and reduces symptoms such as abdominal pain and diarrhea.
  • Ulcerative colitis: contributes to mucosal healing and maintenance of remission in the colon.
  • Eosinophilic esophagitis: diminishes eosinophilic infiltration and improves swallowing difficulty.

How It Works

  • Budesonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and stabilises lysosomal membranes, resulting in potent anti‑inflammatory and immunosuppressive effects within the gastrointestinal mucosa and esophageal tissue.

Side Effects

Adverse reactions may occur with oral budesonide therapy.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial discomfort.
  • Abdominal pain: cramping or discomfort in the abdomen.
  • Oral candidiasis: fungal infection of the mouth.
  • Increased appetite: may lead to weight gain.
  • Fatigue: feeling unusually tired.

Serious or Rare Side Effects

  • Adrenal suppression: reduced endogenous cortisol production.
  • Severe infection: heightened risk of bacterial, viral, or fungal infections.
  • Hypersensitivity reactions: rash, itching, or anaphylaxis.
  • Osteoporosis: decreased bone mineral density with long‑term use.
  • Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients.
  • Mood changes: depression, anxiety, or psychosis.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks.

  • Infection risk: assess for active infections and avoid initiating therapy in uncontrolled infections.
  • Adrenal function: monitor cortisol levels during prolonged treatment.
  • Bone health: consider calcium and vitamin D supplementation for long‑term use.
  • Diabetes management: monitor blood glucose regularly.
  • Pregnancy and lactation: weigh benefits against potential risks; consult obstetric guidance.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Budesonide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adverse effects.
  • Systemic immunosuppressants (e.g., azathioprine): additive immunosuppression heightening infection risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce budesonide levels, diminishing therapeutic effect.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal irritation.
  • Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring.
  • Diuretics: potential for electrolyte imbalance when combined with systemic steroids.

Frequently Asked Questions

Intesticortmono contains budesonide, a glucocorticoid that is prescribed for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, as well as for eosinophilic esophagitis. In each condition, the medication works to reduce mucosal inflammation and help achieve clinical remission.

Budesonide binds to glucocorticoid receptors inside cells, forming a complex that enters the nucleus and alters gene transcription. This process suppresses the production of inflammatory cytokines, reduces leukocyte migration, and stabilises cell membranes, leading to a potent anti‑inflammatory effect in the gastrointestinal tract and esophagus.

The specific dosage of Intesticortmono is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, and response to therapy. Healthcare professionals tailor the dose to achieve optimal therapeutic benefit while minimising potential adverse effects.

Safety data for budesonide in pregnancy and lactation are limited. Prescribers should evaluate the potential benefits against possible risks to the fetus or infant. If treatment is considered essential, it should be undertaken under close medical supervision with appropriate monitoring.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Budesonide has a high first‑pass metabolism, which generally results in lower systemic exposure compared with conventional steroids like prednisone. This property can reduce the incidence of systemic side effects, making it a preferred option for localized gastrointestinal inflammation when appropriate.

Intesticortmono should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Intesticortmono is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include adrenal suppression, which can lead to cortisol deficiency, and an increased susceptibility to severe infections. Patients should be monitored for signs of hormonal imbalance, persistent fever, or unusual infections, and any concerns should be reported promptly to a healthcare provider.

Intesticortmono is contraindicated in individuals with known hypersensitivity to budesonide or any component of the formulation. It should also be avoided in patients with active, uncontrolled infections or those for whom systemic corticosteroid therapy is contraindicated, unless a specialist determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Budesonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT